Review
Cell Biology
Eleni Kalafati, Ekati Drakopoulou, Nicholas P. Anagnou, Kalliopi I. Pappa
Summary: Cervical cancer is a major global malignancy in women. Current therapies are inadequate and cytotoxic, leading to serious side effects. Oncolytic viruses offer a promising treatment option as they selectively infect and kill cancer cells. This review discusses different oncolytic viruses for targeting cervical cancer and their combination with conventional therapies.
Article
Oncology
Clement Anfray, Francesco Mainini, Elisabeth Digifico, Akihiro Maeda, Marina Sironi, Marco Erreni, Achille Anselmo, Aldo Ummarino, Sara Gandoy, Francisco Exposito, Miriam Redrado, Diego Serrano, Alfonso Calvo, Marvin Martens, Susana Bravo, Alberto Mantovani, Paola Allavena, Fernando Torres Andon
Summary: This study demonstrated the superior efficacy of poly(I:C) combined with R848 compared to single treatments or combined with R837 in reprogramming macrophages towards M1-like antitumor effectors in vitro, leading to significant prevention of tumor growth and metastasis in lung cancer and fibrosarcoma mouse models. The therapy also induced systemic antitumoral response and resistance to tumor rechallenge through boosted macrophage cytotoxic activity and T-cell proliferation. Proteomic experiments validated the activation of innate immunity by poly(I:C)+R848 combination, with the key activation of the STAT1 pathway.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Bin-Jin Hwang, Li-Chung Tsao, Chaitanya R. Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, Xiao-Yi Yang, Gangjun Lei, Takuya Osada, Herbert Kim Lyerly, Michael A. Morse, Zachary Conrad Hartman
Summary: This study demonstrates that the suppression of innate immune gene expression in tumor cells is a major factor contributing to the insensitivity of colorectal cancer to immune checkpoint inhibitor treatment. By reintroducing the suppressed gene MAVS, the study found that it can stimulate both local and systemic immune responses against the tumor and enhance the efficacy of anti-tumor immunotherapy when combined with PD-L1 inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Chemistry, Physical
Xiaorong Kou, Tao He, Miaomiao Zhang, Xinyue Wu, Xinchao Li, Rui Luo, Rui Wu, Xinyu Gou, Meiling Shen, Qinjie Wu, Changyang Gong
Summary: A hydrogel-based vaccine (Bridge-Vax) has been developed to activate CD8(+) T cells against tumor antigens by rebuilding the bridge between innate and adaptive immunity. It overcomes the limitations of personalized vaccines in tumor heterogeneity and provides a powerful tool for personalized cancer immunotherapy.
Article
Multidisciplinary Sciences
D. G. Roy, K. Geoffroy, M. Marguerie, S. T. Khan, N. T. Martin, J. Kmiecik, D. Bobbala, A. S. Aitken, C. T. de Souza, K. B. Stephenson, B. D. Lichty, R. C. Auer, D. F. Stojdl, J. C. Bell, M-C Bourgeois-Daigneault
Summary: Vaccination with oncolytic viruses co-administered with tumour antigenic peptides is as efficient as antigen-engineered oncolytic viruses, providing a potential alternative for personalized anti-cancer vaccines targeting patient-specific mutations.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Tianyu Tang, Xing Huang, Gang Zhang, Tingbo Liang
Summary: Oncolytic peptides are highly effective in remodeling the tumor microenvironment and enhancing anticancer immunity by inducing immunogenic cell death. A recent study shows that LTX-315 inhibits PD-L1 expression via ATP11B, thereby enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. This commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, as well as the potential issues and directions in cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Erkko Ylosmaki, Manlio Fusciello, Beatriz Martins, Sara Feola, Firas Hamdan, Jacopo Chiaro, Leena Ylosmaki, Matthew J. Vaughan, Tapani Viitala, Prasad S. Kulkarni, Vincenzo Cerullo
Summary: The study developed a novel cancer vaccine platform based on BCG, which can broaden immune responses to include tumor antigens. Coating BCG with tumor-specific peptides improved antitumor immune responses and increased the number of responders to anti-PD-1 immunotherapy when combined with ICI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Sara Feola, Salvatore Russo, Beatriz Martins, Alessandra Lopes, Gaelle Vandermeulen, Vinciane Fluhler, Camilla De Giorgi, Manlio Fusciello, Sari Pesonen, Erkko Yloesmaeki, Gabriella Antignani, Jacopo Chiaro, Firas Hamdan, Michaela Feodoroff, Mikaela Groenholm, Vincenzo Cerullo
Summary: Oncolytic viruses (OVs) can work as in situ cancer vaccines by directly lysing cancer cells and releasing tumor antigens. However, this mechanism may not always induce a strong T cell response. Genetically modified OVs encoding tumor antigens or coating OVs with tumor antigens can enhance the priming efficiency. In this study, both approaches were tested and characterized for their efficacy as cancer vaccines. Both genetically modified oncolytic adenovirus and PeptiCRAd elicited T cells-specific anti-tumor responses, but PeptiCRAd showed advantages in fast presentation of tumor antigens and adaptability for personalized cancer vaccines.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Tracy W. Liu, Seth T. Gammon, Ping Yang, Wencai Ma, Jing Wang, David Piwnica-Worms
Summary: The presence of immune suppressing myeloid cells in the tumor microenvironment limits the success of immune checkpoint therapy (ICT). In this study, the researchers found that removing or inhibiting myeloperoxidase (MPO) can enhance the response to ICT in aged mice with primary melanoma. The tumor microenvironment and systemic immune landscape experienced significant changes, and repurposing MPO-specific inhibitors showed promising results in combination with ICT.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Marc Pfefferle, Irina L. Dubach, Raphael M. Buzzi, Elena Duerst, Nadja Schulthess-Lutz, Livio Baselgia, Kerstin Hansen, Larissa Imhof, Sandra Koernig, Didier Le Roy, Thierry Roger, Rok Humar, Dominik J. Schaer, Florence Vallelian
Summary: The study revealed that CD40 signaling in Clec4f(+) Kupffer cells triggers anti-CD40 antibody-induced liver toxicity. However, controlled erythrophagocytosis and the linked anti-inflammatory signaling by the endogenous metabolite heme can be exploited to reprogram liver macrophages and prevent necroinflammatory liver disease caused by high-dose administration of anti-CD40 antibodies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Chemistry, Multidisciplinary
DaeYong Lee, Kristin Huntoon, Yifan Wang, Wen Jiang, Betty Y. S. Kim
Summary: The discovery of immune checkpoint blockade has revolutionized cancer treatment, but current immunotherapies are only effective for a small subset of patients. Future advancements in cancer immunotherapy will focus on developing novel therapeutic molecules or immunoengineered cells. Biomaterials can efficiently reprogram and recruit immune cells in tumors to activate T cell immunity against advanced cancers.
ADVANCED MATERIALS
(2021)
Review
Immunology
Zhen Yang, Ruxue Liu, Minghan Qiu, Hanwei Mei, Jie Hao, Teng Song, Ke Zhao, Dandan Zou, Huaqing Wang, Ming Gao
Summary: Traditional Chinese medicine has a long history in China and has been recently prioritized in the 14th Five-Year Plan for its development. ERIANIN, a component of Dendrobium, has various pharmacological effects and has shown broad-spectrum antitumor properties. This review aims to systematically summarize the research on ERIANIN and provide insights into its future development in combined immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Jianyu Ye, Jieliang Chen
Summary: IFN therapy has unique advantages in treating chronic hepatitis B, but its efficacy is limited and side effects are common. To seek a cure for HBV, improving IFN therapy and combining it with other antiviral agents may be considered.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Louise M. E. Muller, Gemma Migneco, Gina B. Scott, Jenny Down, Sancha King, Basem Askar, Victoria Jennings, Babatunde Oyajobi, Karen Scott, Emma West, Christy Ralph, Adel Samson, Elizabeth J. Ilett, Munitta Muthana, Matt Coffey, Alan Melcher, Christopher Parrish, Gordon Cook, Michelle Lawson, Fiona Errington-Mais
Summary: The study demonstrates that reovirus can reduce MM tumor burden and myeloma-induced bone disease, increase NK cell and CD8(+) T cell numbers, activate these cells, and upregulate effector-memory CD8(+) T cells. Reovirus is able to kill MM cells by activating NK cells and MM-specific CD8(+) T cells, suggesting that reovirus-induced immunotherapy should be combined with agents that enhance antitumor immune responses.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Haibo Sun, Thomas G. Martin, John Marra, Denice Kong, Jonathon Keats, Sandrine Mace, Marielle Chiron, Jeffrey L. Wolf, Jeffrey M. Venstrom, Raja Rajalingam
Summary: The study revealed that specific genetic makeup of patients can influence their response to Isa-lenalidomide-dexamethasone therapy, with patients carrying KIR3DL2 and HLA-A3/11 plus high-affinity FCGR3A-158V allele showing improved progression-free survival. Conversely, patients with KIR2DL1 and HLA-C2C2 combination may have a lower response to this treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
